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ABSTRACT

Computational modeling approaches have lately been earning their place as viable tools
in drug discovery. Research efforts more often include computational component and the usage
of the scientific software is commonplace at more stages of the drug discovery pipeline.
However, as software takes on more responsibility and the computational methods grow more
involved, the gap grows between research entities that have the means to maintain the necessary
computational infrastructure and those that lack the technical expertise or financial means to
obtain and include computational component in their scientific efforts. To fill this gap and to
meet the need of many, mainly academic, labs numerous community contributions collectively
known as open source projects play an increasingly important role. This work describes design,
implementation and application of a set of drug discovery workflows based on the CHARMMing
(CHARMM interface and graphics) web-server. The protocols described herein include docking,
virtual target screening, de novo drug design, SAR/QSAR modeling as well as chemical
education. The performance of the newly developed workflows is evaluated by applying them to
a number of scientific problems that include reproducibility of crystal poses of small molecules
in protein-ligand systems, identification of potential targets of a library of natural compounds as
well as elucidating molecular targets of a vitamin. The results of these inquiries show that
protocols developed as part of this effort perform comparably to commercial products, are able
to produce results consistent with the experimental data and can substantially enrich the research
efforts of labs with otherwise little or no computational component
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CHAPTER ONE:
INTRODUCTION
The Need for Web-Based Open Source Drug Discovery Platforms
The concept of open source application development has emerged with the popularization
of the World Wide Web as a platform for technical and scientific collaboration. The ability to
communicate, share ideas and individual contributions to achieve a single objective gave rise to
group efforts where each participant could advance the common goal independent of their
physical location, affiliation or even technical background. Such a concept promotes the
participation of people that while having a wide range of skills have a common set of interests or
even passions. This allows the participants to contribute “freely”, often without an expectation of
monetary reimbursement purely for the sake of advancing the field and serving the community of
people with similar interests. The motivation behind such undertakings is especially strong when
the project contributes to satisfying a need of significant importance, a need that would be
difficult to meet without such a collective effort.
Drug discovery is a field where, at first glance, such an open community effort is an
unlikely approach. Historically the cost and effort of developing a new drug has largely confined
successes to large pharmaceutical companies or otherwise well-funded research institutions.1
Development and use of computer aided drug design (CADD) techniques has provided numerous
benefits to the overall process and has been acknowledged by the award of the Noble Prize in
Chemistry in 2013.2 However the expertise required to create powerful commercial software
packages has resulted in high licensing costs,3,4 thus limiting access to academic groups.
1

Fortunately, this trend has started to shift with the emergence of freely available software such,
as Autodock5 and several other packages,4 largely developed by the academic computational
chemistry community. However, for the most part, these software packages require familiarity
with CADD methodologies and are better suited for computer savvy users that are at least
comfortable if not familiar with the computational component of drug discovery.6 This has
hampered the proliferation of CADD tools into less computationally minded drug discovery labs.
The need for intuitive and easy to use CADD solutions has largely been met by the commercial
software companies such as Accelrys, Schrödinger, and others that have incorporated full
featured graphical user interfaces (GUI) into their programs.7–9 However, as alluded to above, the
cost of these packages is typically prohibitive to academic groups and/or institutions. Further, it
has proven increasingly difficult to strike a balance between software that is user-friendly yet
incorporates a wide range of advanced functionality and customizability. Another aspect of
concern is portability. For example stand-alone software that requires local installation on every
computer, may find less use in today’s world1 where researchers expect both the application and
the data to be accessible from any machine on any platform from any location.10
Another hurdle, faced by the non-expert, to incorporating computational modeling into
drug discovery efforts is the difficulty of obtaining reliable small molecule parameters.11–13 Most
widely used and well tested force fields have been developed with proteins and nucleic acids
rather than small molecules in mind14. Until recently this has meant that drug-like molecule
parameters have been less reliable, with assignment often arbitrary. Lately, however, there has
been a significant amount of effort devoted to improving the reliability of small molecule
parameters and developing efficient protocols to generate them for a much greater and more
diverse chemical space11,12,14,15.
2

The applications development of which is described in this work have been designed with
several criteria in mind:
1. Incorporation of a range of drug discovery methods to aid researchers at different
points in the drug discovery process. Such methods include molecular modeling and
simulations, docking, de-novo drug design and chemoinformatics.
2. All the data produced by the applications or uploaded by the user remains accessible
indefinitely and is tied to the user account and secured by the verification of login
credentials. All the jobs run independently and do not require active user session. The
results of user jobs along with all the input and output file are stored in the database
and are available for access at any time in the future.
3. Pre-loaded public compound library is available for docking and virtual screening
jobs in addition to user supplied compounds.
4. Integration with outside resources such as protein, compound and assay data
repositories.
5. Usable by computational novices and advanced users alike.
Primary users targeted by the application include small academic labs and any other labs
that don’t have financial means of obtaining commercial drug discovery packages or don’t have
the expertise to run and maintain drug discovery applications without having access to
computational core facilities. Some more specific examples of potential users are:


Medicinal chemistry lab that would like to use computational techniques at early stages
of discovery to get lead ideas



An experimental lab that would like to supplement their findings with additional rationale
based on computational methods
3



A group that would like to build hypothesis for lead optimization using a set of already
obtained experimental data

Challenges of Open Source Projects
Open source approach to developing drug discovery applications has a number of
challenges. Some are inherent to the concept of open source approach itself while others are
more specific to the field of computer - aided drug discovery. The very nature of collaborative
open source projects means that there are multiple contributors. Aside from the more obvious
factors such as different geographical locations, which internet more or less successfully
alleviates, there are other issues to consider. It is likely that there may be significant differences
between technical backgrounds of the contributors. Since in this case the project largely deals
with computer programming, the most evident manifestation of these differences may be the
variety of programming languages and development paradigms the contributors may be
comfortable with. This presents a two-fold challenge. First, at the earliest stages of the project
some common coding framework should be chosen such that new contributors find it easy
enough to transition to it even if they come from a different background or in general have less
advanced technical skills. Second, as the project progresses the coding standards should be
adhered to and kept within the common framework. The most obvious benefits of these steps
will be the fact that a new developer will be able to get up to speed quickly, will be able to read
and understand the code of other developers, and most importantly will be able to follow the
same design and coding patterns. This will help prevent the project from becoming too
fragmented over time, allow participants to better integrate their individual contributions into the
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overall project as well as make maintenance and upgrades easier. The latter is especially
important for open-source community efforts as the contributor turnover is usually high.
Another largely technical aspect of any open-source effort is the platforms. In this context
platform encompasses such concepts as computer architecture and operating system. Both the
platform on which the development is done and on which the final product is served to the enduser are important. Even though most programming languages or development frameworks strive
to be platform-independent, in practice platform differences may pose challenges ranging from
syntax differences to binaries or compiler incompatibilities. Similarly, packaging a final product
as a Windows® executable will likely mean that it will not execute on a Linux based machine.
The end-user platform consideration is particularly sensitive in the age of mobile computing
where users expect their applications served on wide variety of mobile devices.
The issue of data and information standards is also an important consideration when it
comes to open-source efforts and it is by no means unique to the field of CADD. However in the
context of this work it is proper to consider cases specific to drug discovery, storage and
representation of chemical information. A wide variety of structural data formats makes for an
important consideration when designing an open-source application whose functionality largely
hinges on the ability to process chemical structural information. In principle, suitable plfug-ins
can over time be developed by community contributors to allow the application to speak any
dialect of a chemical language. However a project whose success depends on the community’s
acceptance risks alienating its users if a basic support for most common formats is not provided
from the beginning. Another aspect that, to a degree, deals with standards is compatibility with
other commercial, free or open-source tools available to the community. CADD is a large and
growing field. Computer techniques find use in many stages of the drug discovery process
5

ranging from hit finding to lead optimization, toxicology predictions and beyond. In addition
there may be multiple computational approaches or software applications to perform similar
tasks. With this in mind the open-source application has to be able to both accept as input and
produce the output compatible with other programs that the user may potentially utilize as part of
their research.
A more practical aspect of developing a scientific application is its ability to crunch a lot
of data fast. In other words, performance is very important consideration. From running an
extended molecular dynamics simulation on a many atom system to virtually screening a large
compound library, the application has to be able to perform such computationally intensive tasks
in a reasonable time. In addition the execution pattern has to be able to take advantage of
common multi-processor or high performance computing (HPC) architectures in order to spread
the computational load among many worker threads.
Another important point to consider when developing an open source application is its
ability to be expanded, deployed on outside resources or adopted for a particular need. The level
of difficulty associated with these tasks would directly correlate with the application’s pool of
willing contributors and its ability to serve as the basis for independent projects.
Finally, the most important aspect of developing any scientific application is the
soundness of the methods that it implements and an ability to reasonably validate the results that
it produces. The CADD community is a growing one and there is no shortage of contributors of
methods in many of its areas. This is a coin of two sides however; as there is a choice of quality
methods developed and peer reviewed on one side and the challenge of integrating this diversity
of methods and tasks into a cohesive workflow. The latter represents a particular challenge and
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in addition to addressing the above challenges is one of the primary foci of the work presented in
this manuscript.
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CHAPTER TWO:
DEVELOPMENT OF THE CHARMMING WEB USER INTERFACE AS A PLATFORM
FOR COMPUTER-AIDED DRUG DESIGN

Note to Reader
Reprinted (adapted) with permission from Yuri Pevzner †, Emilie Frugier ‡, Vinushka
Schalk †§, Amedeo Caflisch ‡, and H. Lee Woodcock *† Journal of Chemical Information and
1

Modeling 2014, 54, 2612-2620 Copyright 2014 American Chemical Society
The publication follows; supporting information can be found in Appendix A.
CHARMM Interface and Graphics Platform
The CHARMM interface and graphics (CHARMMing)1 is an open source Web interface

to the popular macromolecular modeling package CHARMM.2,3 The goal of the CHARMMing
project is to provide a platform-independent Web-based front-end that allows its users to set up
and perform a wide variety of molecular modeling tasks. At its inception CHARMMing project
was designed to satisfy some of the unmet needs of the drug discovery community as well as
address a number of the implementation challenges mentioned in chapter one. CHARMMing is
built using Django4 framework which is based on a widely used Python5 scripting language.
†

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE205, Tampa,
Florida 33620-5250, United States
‡
Department of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland
§
Department of Natural Sciences, New College of Florida, Sarasota, Florida 34243, United
States
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Python is a high level language that is relatively easy to learn even for somebody with limited
exposure to programming while at the same time is adherent to the more advanced objectoriented programming principles. At the same time Django uses a consistent model-view
paradigm that facilitates consistency of the code structure and makes it easy to add and
effectively encapsulate new features, modules and functionality. Although Django uses a
relational database (MySQL6 in the context of this project) as a back-end storage engine,
database access is facilitated via an intuitive ORM (object-relational mapping) API (application
program interface) that allows database operations to be performed even by developers with no
knowledge of SQL (Structured Query Language) that is natively used to operate on relational
databases. The use of above technologies makes contribution to CHARMMing project possible
from a variety of platforms. Moreover the end product of the project is a web-based application.
This means that the end-user functionality is served via a web browser, thus eliminating the
issues of cross-platform compatibility as modern browsers are able to serve content rather
consistently over a wide range of computer architectures, operating systems and devices.
CHARMMing’s basic functionality includes structure processing, setting up and running
molecular dynamics simulation and other molecular modeling tasks. It directly interfaces with
PDB (Protein Data Bank)7 to retrieve structures and includes an internal parser and structure
processing mechanism to prepares biological systems of interest for molecular modeling studies.
CHARMMing’s infrastructure includes PBS (Portable Batch System)8 for scheduling of jobs
submitted by multiple users and the jobs’ distribution over available HPC resources.
CHARMMing’s users range from small academic labs, that benefit from the portal’s
functionality, to educators, that include molecular modeling in their curricula and use the portal
to facilitate their teaching.9–11
10

CHARMMing is open source and the code can be downloaded for free. In addition
CHARMMing comes with an automated installer that can be used to install an instance of
CHARMMing infrastructure and the interface on a Linux based architecture. This is particularly
useful when developing a custom and possibly proprietary application using CHARMMing with
all or some of its functionality as a starting point. The development of the VTS (Virtual Target
Screening)12 server described later in this work is an example of such use of CHARMMing. The
remainder of this chapter describes the development and evaluation of fragment-based docking
protocol as an extension of CHARMMing functionality.

Fragment-based docking protocol in CHARMMing
Implementation Details
Target Preparation
Target proteins begin their preparation via CHARMMing’s structure submission section.
Here, tasks such as the addition of hydrogens, identification of any non-protein moieties, and
assignment of final parameters are carried out (using the latest, CHARMM36 protein force
field).13,14 Co-crystallized small molecules (i.e., ligands) are automatically parameterized using
the CGenFF.15 Specifically, ligand atom-typing and parameterization is performed by
sequentially attempting several automated parameterization tools. The default order is: (1)
Param-Chem,15–17 (2) MATCH,18 (3) Antechamber,19 and (4) GENRTF.20 As an alternative to
the default order a user can specify the exact build procedure to use for parameterization.

Compound Library and Ligand Upload
CHARMMing docking module provides a pre-loaded library of drug-like compounds for
11

virtual screening experiments. The library consists of approximately 8,000 molecules from the
Maybridge HitfinderTM set (www.maybridge.com). All of the provided molecules have been
atom typed according to CGenFF convention to comply with CHARMM requirements and
confirmed to decompose into at least 3 sufficiently sized fragments to meet the fragment-based
docking criteria. CHARMMing also allows users to upload ligands by providing a coordinate file
in mol2 format. Upon uploading, the ligand undergoes atom-typing and parameterization as
previously described. The ligand and corresponding parameter, topology, and structure files are
then saved on disk as well as cataloged in the database. The parameters for pre-loaded and useruploaded ligands contain penalty scores that reflect the quality of the bonded parameters and
partial charges.17 These penalties should be used by the user to make decisions regarding
compounds that should be discarded due to the lack of quality parameters. Unlike the pre-loaded
compound library, any user-uploaded ligands are restricted to their account only and are not
visible to other users. The user is also given the ability to create custom sets of molecules based
on any pre-loaded or user uploaded compounds. This can be done via the “Ligand Sets” section
(Figure 1) of the docking module. Any custom or pre-loaded set can be docked in its entirety or
by selecting individual molecules on the docking submission page (Figure 2).

Binding Site Definition
To provide maximum flexibility with respect to job setup, two different ways of
specifying the binding region of interest are implemented. The first approach identifies the
binding pocket using the position of a co-crystallized ligand that may be present. In this case,
when launching a docking job a user is presented with a list of all co-crystallized small
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Figure 1. The “Ligand Set Details” page allows the user to manage custom ligand sets. The user
can define and describe a custom ligand set as well as add ligands to it from any of the other sets
including the pre-loaded public library.

molecules along with their 2D structural representations. Once the desired small molecule is
chosen, the binding site is defined via proximity to the aforementioned small molecule. In cases
where no co-crystallized ligand is present, or if a user simply wishes to investigate alternative
binding sites, we have implemented an interactive and graphical binding site definition tool
(Figure 3). To use this tool, two residues should be selected that roughly correspond to the edges

13

Figure 2. The “Submit Docking Job” page. This page presents the user with the ability to select
the target coordinates for docking, define the binding pocket (vide infra), and select ligands to
dock from the list of available small molecules. The native ligands and ligands available for
docking can be visualized in 3D using the embedded visualization application.
of the desired binding region. The midpoint between these residues is then determined and
defined as the approximate center of the binding site. Based on a user-defined radius, a list of all
residues within this distance is compiled and both visually highlighted and presented as a list.
The user can then add or remove residues to/from this list by either modifying the text of the
residue list, changing the specified search radius, or modifying it via graphical selection (i.e.,
clicking). Ultimately, all user-defined binding sites are saved and presented as options, with any
existing co-crystallized ligands, at the docking job setup page.

14

Figure 3. The binding site definition page. This page provides the user with multiple ways to
select a custom binding site. This can be done either by manually typing in the residue numbers,
graphically selecting residues, or defining the centroid and specifying the radius in Å.

Docking Protocol
Docking algorithms used in this protocol are based on the popular grid-based paradigm,
used by most current docking programs.21–26 In this approach the solvent accessible surface area
of the target and the ligand as well as the target’s binding site are discretized onto a 3D lattice.
The lattice then either stores information about the atoms enclosed by a cubic unit of the grid or
contains the potential contributions projected onto the grid’s vertices. Pre-computed grids allow
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for efficient calculation of both van der Waals and electrostatic contributions to the scoring
function, facilitating rapid evaluation of ligand placements within the binding site.
The docking procedure consists of several steps where different programs perform
distinct tasks. To streamline the communication between the programs and ensure compatibility
of input and output data a series of scripts were written in Python, Perl, and Linux shell scripting
languages. The OpenBabel27 file conversion utility was used to inter-convert between different
representations of the protein and compound structures. The program MATCH30 was used to
generate CGenFF compatible topologies and parameters. The fragment-based docking protocol
implemented in CHARMMing is outlined in Figure 4 and described below:
1.

Each compound to be docked is first broken down into fragments. A fingerprint

describing chemical richness is generated for each fragment and its parent compound.
The three most chemically rich, but not necessarily different, fragments are identified to
serve as anchors for docking. These steps are carried out by the program DAIM
(Decomposition and Identification of Molecules).28

2.

The user then identifies the binding site to be used in the docking job. All non-

protein, non-solvent compounds present in the submitted target structure are displayed on
the “Submit Docking Job” page (Figure 2). Based on the user selected compound, the
proximal residues are identified and the binding site defined.
3.

The previously identified anchor fragments (step 1) are then docked into the

binding site using the program SEED (Solvation Energy for Exhaustive Docking).29 The
placement of fragments within the binding site is determined by matching either the
direction of polar vectors between ligand and receptor atoms to form a hydrogen bond or
the apolar vectors on the solvent accessible surface area of the ligand the receptor. The
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A

B

Figure 4. Schematic depiction of fragment-based docking protocol implemented into
CHARMMing. A- The main stages of the docking: decomposition by DAIM, fragment
docking by SEED, and ligand placement by FFLD. B – Flow chart representing the
sequence of the procedures of the protocol. CHARMM(ing) world grayed area represents
the steps which include CHARMM compatible protein-ligand system.
SEED score, used in fragment placement, accounts for the solvent effects by including
terms for both receptor and fragment desolvation as well as a solvent screened receptorfragment electrostatic interaction term.
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4.

The docked fragments are reconnected into the original ligand while undergoing

refinement using the FFLD (Fragment-based Flexible Ligand Docking) program.30 FFLD
uses a genetic algorithm that generates and evaluates populations of conformations and
positions them within the binding site, as guided by fragment anchor locations. The
fitness of a placed con- formation is evaluated using a scoring function that is aimed at
approximating the steric effects as well as hydrogen bonding contributions of the proteinligand interactions. This function includes intra-ligand and protein-ligand van der Waals
interaction terms as well as polar contributions based on the number of hydrogen bonds
and unfavorable donor-donor and acceptor-acceptor interactions.
5.

Poses generated by FFLD that are within a user defined energy cutoff (10

kcal/mol by default) are then clustered using a leader clustering algorithm implemented
in the program FLEA (FFLD Leader Clustering).31
6.

Following the clustering, the protein-ligand complex is converted to native

CHARMM format and saved. Using these files, in addition to the CHARMM protein and
generalized force fields (i.e., CHARMM36 and CGenFF), protein structure (psf) and
coordinate (crd) files are generated. Each ligand then undergoes one thousand steps of
minimization using the adopted basis Newton-Raphson (ABNR) algorithm while keeping
protein atoms fixed. The “minimized” protein-ligand complexes are then scored using
SEED and FFLD in their “evaluation only” mode, producing their own estimation of
electrostatic, van der Waals, and total energy contributions for each pose. The final
ranking of the docked poses is performed using a consensus approach. For this, energies
(i.e., interaction energy from CHARMM and total energies from SEED and FFLD) are
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used to create three lists in which individual poses are sorted and ranked. The final rank
of each pose is then set to

Job Submission and Monitoring
When a docking job is launched, the based queuing system TORQUE51 accepts the job
as a wrapper shell script that controls the entire docking procedure. Using the interface, a job can
be monitored in real-time as it progresses and generates final poses for each docked compound.
Basic job statistics such as submission time and job status can be monitored along with the
output file reflecting the job progression (Figure 5). In addition, important files associated with
job progress and results (e.g., final docked ligand poses, job output, etc.) can be downloaded to a
local disk. Protein, ligands, compounds in the library, and final docked poses can all be
visualized directly in CHARMMing. The 3D structure of each of the above elements can be
rendered with the JSmol38 or GLmol39 visualization tools. Structures can be visualized using a
variety of representations to highlight important structural features or interactions of the
molecules and their complexes.

A walk-through outlining the entire process of performing a self-dock on a sample
system is included in the tutorial covering basic CHARMM and CHARMMing functionality at
www.charmmtutorial.org. Additionally a docking lesson that guides a user through the selfdocking procedure has been added to the lessons section of the CHARMMing website.

Performance and Local Execution
Currently, all docking jobs executed via the Web interface are carried out sequentially.
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Figure 5. The “Job Details” page. This page provides general job information as well as the list
of docked poses and their respective scores. The docked poses can be visualized in 3D within the
binding pocket of the protein using the embedded visualization application. An archive of the job
directory can also be downloaded from this page for execution on local resources.

However, after the initial setup of the docking job, all necessary files are available for download
and execution on local computational resources. To improve performance of this procedure, we
have developed a protocol that can be carried out in parallel as outlined in Figure 6. This is
achieved by spawning a new execution branch for each of the most time consuming steps in the
protocol via a user-modifiable job queuing command. For example, each fragment of each
molecule is docked (step 3, vide supra) as a separate submitted job. Once all of a molecule’s
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anchor fragments are docked, the placement of a ligand within the binding site by FFLD is also
spawned as a series of separate jobs. Furthermore, to increase sampling by FFLD, and improve
performance, the protocol performs multiple docking iterations per ligand, again each as a
separate job. Thus, instead of one docking job that attempts to sequentially sample a large
conformational space per ligand, multiple shorter iterations with different random seeds are run
in parallel, taking less real time and still sufficiently sampling ligand conformational space. The
number of iterations per ligand as well as the amount of energy evaluations per iteration are all
user modifiable parameters.

In order to execute a job on local resources the following programs need to be
downloaded and installed: VMD,40 DAIM, SEED, FFLD, FLEA, MATCH, and CHARMM.
Except for CHARMM, all of these programs are free for academic use. VMD can be
downloaded from the University of Illinois at Urbana-Champaign’s Theoretical and
Computational Biophysics group www.ks.uiuc.edu/Research/vmd). DAIM, SEED, FFLD, and
FLEA can be obtained from the University of Zurich’s Computational Structural Biology lab
(www.biochem-caflisch uzh.ch/download). Further, a more general description of the installation
process is included as part of the CHARMM tutorial and can be found at the following address:
www.charmmtutorial.org/index.php/Installation_of_CHARMMing.
Once the job directory is downloaded and the software is installed on local resources, the
provided settings file should be used to specify the location of program executables. In addition,
job details (e.g., protein file name, number of docking iterations, clustering energy cutoff, etc.)
can be modified via the settings file. This file is also where PBS/TORQUE commands can be
modified for local resources. Because there is no limit to the number of possible parallel
processes spawned, the protocol checks for available resources and will wait for current
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Figure 6. Parallelization of the docking protocol. The parallelization is achieved by spawning
new job execution threads at both the fragment docking (i.e., one per fragment) and ligand
placement (i.e., one per iteration per ligand) steps. Clustering and scoring threads are also
spawned for each docked ligand.

processes to complete if the queue is full. The protocol will automatically take advantage of all
available resources to speed up job completion while at the same time adhering to the local
queuing system policies.

Results and Discussion
To assess the performance of the docking protocol a diversity set was constructed from
the publicly available CCDC/Astex test set,41 containing high resolution x-ray complexes, and an
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augmented version of that set, which has been used to compare the performance of a number of
docking programs.42 Our final set contained 24 protein - ligand complexes with x-ray resolutions
ranging from 1.50Å – 2.30Å. In particular, we selected complexes where the ligand could be
decomposed into three fragments (i.e., at least three rotatable bonds) using the default settings of
DAIM; as the ultimate goal was to evaluate the implementation of the decomposition based
approach.
Self-dock validation involved removing the co-crystallized ligand from the complex, selfdocking it via the fragment-based protocol, and comparing the docked pose to that of the original
crystal structure. Each complex was processed using CHARMMing’s “Submit Structure” section
that downloads the structure based on the PDB code, adds hydrogen atoms, and prepares the
structure for modeling using CHARMM. Further, each system containing the protein, solvent
and ligand molecules was briefly minimized for 100 steps using the Steepest Descent method
followed by 1000 steps of ABNR using CHARMMing’s “Calculations” module. Using the
“Ligand Upload” section of CHARMMing’s docking module the previously downloaded ligand
was processed. The docking calculation for each minimized system was set up by selecting a
native ligand to define a binding pocket and user-uploaded ligand for docking, all from the
“Submit Docking Job” page of the docking module. The progress of each job was monitored
using the job monitoring section of the docking module. To assess the performance of the
dockings, root-mean-square deviation (RMSD) between the heavy atoms of the docked poses
and the crystal structures was calculated using VMD.
To compare the docking protocol’s performance, a commercially available docking
package was also used. Self-dockings were performed using Schrödinger’s Glide22–24,43 Standard
Precision (SP) docking protocol. Glide’s SP protocol attempts to dock multiple conformations of
23

a ligand into a receptor grid, subsequently calculating the effective ligand-receptor interactions
using a proprietary scoring function. Conformational sampling of the ligand is achieved via
varying torsion angles around rotatable bonds. Prior to docking, each target was prepared using
Maestro’s44 Protein Preparation Wizard.45–49 The preparation included removal of solvent
molecules, addition of hydrogens, and brief minimization. As Glide is also a grid based docking
protocol, the grids, similarly to CHARMMing’s procedure, were built using the co-crystal ligand
to define the binding region. The native ligand was removed and self-docked using default
parameters of the SP docking protocol. The poses with the best docking scores were used to
calculate their respective RMSD from the crystal structure using VMD.
Table 1 reports the RMSD of poses generated by CHARMMing’s fragment-based
docking protocol and Glide SP docking (w.r.t. crystal structure). Results reported from
CHARMMing’s fragment-based docking protocol correspond to the pose closest to the crystal
structure. This set yields a 71% success rate using RMSD <2.0 Å as the metric; this criteria is
commonly employed for evaluating the performance of docking algorithms.42,50–52 This clearly
shows that the protocol can successfully recover the crystal pose in the majority of the cases.
Optimization of the consensus scoring function is planned as part of the future improvements to
the protocol. Nevertheless, virtual screening is known to suffer from high false-positives rate,
which does not diminish its value in drug discovery as the unfit compounds are screened out
during the experimental stages of the discovery campaigns.53 Regardless, we are encouraged by
the success of fragment-based docking, which shows approximately the same performance as
widely used docking programs, i.e., within the range 40% – 90%.42,50–52
The fragment-based approach that was implemented into CHARMMing yields a
substantial amount of information about the characteristics of each docked pose. At each
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Table 1. RMSDs of the docking poses generated by CHARMMing’s fragment-based docking
protocol and Glide SP and the success rates (defined by the percentage of the ligands whose
reported RMSD is below 2.0Å). “Best RMSD” refers to the pose closest to the crystal structure.
Glide SP RMSD is of the top scoring pose of Glide’s standard precision docking.

step, from decomposition to minimization of docked poses, users have the ability to closely
analyze results. The binding modes of each individual fragment can be inspected and a number
of modifiable parameters, such as decomposition criteria, can be used to optimize the protocol.
Moreover, information gained from docking a fragment library into a particular target can be
used to mine large libraries for compounds containing those fragments that form the most
favorable interactions with the target.54–56
There are potentially a number of improvements that can be made to improve the
performance and usability of CHARMMing’s docking protocol. The most obvious limitation is
the current requirement of three fragments to be used as anchors. As can be seen by the number
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of ligands eliminated from the original benchmarking set, this limits the applicability of this
protocol in its current form to medium to large sized molecules with a sufficient number of
rotatable bonds. Although partially this problem can be alleviated by decreasing the fragment
richness threshold at the decomposition step, this will only increase the “eligibility” rate of
molecules by a small margin. Alternatively, when docking these small and/or rigid molecules is
desired, the decomposition step could be omitted at which point the molecules would undergo
docking only by SEED. This however will require prior conformation sampling step as SEED
currently does not sample the internal conformation of docked fragments. The conformational
sampling of the fragments is an obvious improvement to the docking protocol even in its current
state. This addition will help ensure that larger fragments sample their orientations within the
binding site while varying their internal geometry, thus ensuring greater enrichment of anchor
positions for the final ligand placement. Efforts to incorporate these functionality improvements
are currently underway.

Conclusions
This work has described the implementation of a fragment-based docking protocol into
the CHARMMing Web interface. The protocol allows users to perform docking and virtual
screening calculations online as well as generates self-contained scripts to execute these in
parallel on local HPC resources. The performance of the docking protocol was evaluated by
carrying out the series of self-dockings and comparing the results against a top commercial
docking package. The fragment-based docking protocol yielded results comparable to both the
commercial package used herein and a wide variety of additional docking software. Specifically,
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the rate of recovering the correct x-ray pose with CHARMMing’s protocol was 71%, well within
the 40% – 90% range that numerous benchmarking studies have reported.
While the scoring function that CHARMMing uses to rank poses can still be improved,
the tool lays substantial ground work for allowing academic labs to set up and perform molecular
docking and virtual screening studies. It is important to note that the protocol is able to create
CHARMM formatted protein-ligand systems giving users the ability to access the wide range of
functionality that exists in CHARMM. For example, docked poses can easily be refined with MD
simulations and pre-docked proteins can be coupled with simulations or normal mode analysis to
proceed via an ensemble docking approach. These, in addition to other improvements are
currently being developed.
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CHAPTER THREE:
DEVELOPMENT AND APPLICATION OF THE VIRTUAL TARGET SCREENING
PROTOCOL
Development of the Virtual Target Screening Server
Methodology Background
Active development and, in large part, acceptance of docking algorithms and software in
recent years has allowed the concept of virtual screening gain the status of a widely used tool
during early stages of drug discovery.1–5 Virtual screening (VS) involves docking of a set of
small molecules into a binding site of a target of interest represented by a computer model.
Depending on the availability of computational resources and the nature of the docking
algorithm used, rather large (millions of compounds) libraries of molecules can be docked in
such manner. VS represents a quick and less thorough and less expensive sweep of the chemistry
space than most other computational or experimental techniques. This allows researchers to start
with a broader representation of the chemistry space and narrow down the list of potential drug
candidates committing additional computational and experimental resources to a more focused
set of compounds further down the discovery “funnel”.1–5
The idea of virtual target screening (VTS) is based on the same molecular docking
principles, however is applied in reverse, hence its other common names - inverse docking or
virtual counter - screening. VTS involves docking of a single molecule of interest (MOI) into a
set or a library of proteins. Thus, VTS’s applicability in the context of a discovery project
becomes rather different from that of the conventional VS as VTS is applied at later stages of
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drug discovery. The MOI, as its name suggests, is usually a chemical substance of particular
interest. MOI may be a hit that resulted from a VS campaign, or most commonly it is a lead or a
drug candidate. In the latter case VTS can help gain insight into promiscuity of the lead
compound or its selectivity towards a particular target. VTS, due to its very nature, is an
approach to take when drug repurposing or repositioning is sought. In this case the MOI is often
an already existing approved drug. However MOI can also be a drug candidate that failed at a
later stage of development for a particular indication and an alternative mode of action is being
probed.
VTS is an approach that is beneficial at multiple stages of drug discovery and has the
potential to save substantial costs and efforts by identifying problematic compounds at earlier
stages of the discovery. It can also help find new directions in the development of a
pharmaceutical agent, gain important insight into the relationships between different ligand and
protein families and help identify biological targets of known chemical substances. The
remainder of this chapter focuses on the implementation of the VTS server on a private network
of H. Lee Moffitt Cancer Center using CHARMMing open source framework as its base. In
addition, two examples of applicability of VTS protocol in the context of drug discovery are
presented. First example focuses on identifying potential targets for natural products, while the
second case describes the application of VTS to search for biomolecular targets of vitamin E δtocotrienol.

VTS Protocol
There exist a number of systems based on the concept of virtual target screening.6–9
Although the main goal remains essentially the same, different approaches have been taken to
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arrive at it. Some implementations compare MOI to known actives, some put emphasis on the
comparison of binding sites. While these approaches are useful and even successful each in their
own way, the problems still remain. Lack of known actives with sufficient affinities for a
particular target, insufficient amount of structural information to thoroughly define special
descriptors of binding sites all present challenges.
VTS protocol implemented at the Moffitt Cancer Center uses a procedure developed by
Santiago et.al.10 The procedure includes a calibration step for each protein in the database. The
calibration is intended to establish standards that an MOI should meet in order to be interpreted
as a “hit” according to the protocol. The calibration involves docking of the National Cancer
Institute (NCI) Diversity Set I2 consisting of structures of 1990 drug-like compounds and
recording the average docking scores of top 20 and top 200 scoring compounds as well as overall
average and Boltzmann weighted average. The calibration is performed on each of the 1,567
protein structures in the VTS database. Upon docking of MOI, the docking score of the MOI is
compared to the top 20 average for that protein and if MOI scores better it is considered as “hit”.
If a screen results in a small number of hits, the criteria can be expanded to the top 200 average.

VTS Web-based interface
To facilitate the application of the VTS protocol, a web-based interface that provides a
user friendly, quick and automated tool for docking MOIs into collections of user-defined
proteins was developed. The framework for the online VTS interface is based on the open
CHARMMing package. Publicly available installation of CHARMMing framework was used to
deploy it on a server that was a part the private network of Moffitt Cancer Center. The
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installation has provided basic out of the box components that included database storage engine,
user management system, batch job scheduling infrastructure and a user interface with basic
structure processing and job submission and monitoring functionality. The graphical Virtual
Target Screening (gVTS) system includes tools necessary to set up and initiate VTS experiments.
Functionality implemented in the context of this project includes the following:


Maintain a library of protein grids for docking of small molecules.
o User-prepared grids, based on the proteins of interest can be uploaded and stored
in the internal database.
o Ability to create custom grid sets that can represent structures specific to a given
VTS experiment.



Maintain database of MOIs.
o User can submit MOIs either by uploading the Cartesian coordinates or by
drawing a molecule via a 2D chemical drawing interface, JChemPaint
(jchempaint.sourceforge.net), which is included in gVTS (Figure 7).
o All submitted MOIs are atom-typed and energy minimized with MacroModel.11



Initiate VTS runs and analyze results
o VTS jobs can be set up with any number of MOIs against either the entire library
of proteins or a custom created subset.
o Job runtime estimation algorithm predicts an approximate execution time based
on the number of MOIs, rotatable bonds per MOI, and number of screened
proteins.
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Job scheduling and queuing system provided by the CHARMMing interface allows for
submission of multiple jobs and can be interfaced to popular queuing systems such as
Torque, PBS, and sun grid engine (with slight modifications).



Complete, up to the second, information on any job currently running or run in the past is
available and includes but is not limited to the status of the job, information about any
resulting hits, structures being screened/hit, log, and output files. In addition, the user is
able to visualize the docking pose of any MOI in a protein hit (Figure 8).



User authentication system
o To ensure privacy of the data, the Django/CHARMMing based user
authentication system in combination with database identifiers protects each
user’s information such as MOIs, protein structures, jobs, etc. and allow access
only by authorized persons.
The interface has been developed using the underlying CHARMMing infrastructure at

the time of the implementation using Python 2.6 programming language and the Django 0.96
object framework. A MySQL 5.1.37 database is used to maintain system information and user
generated data. Perl scripts provide the interface to the Schrodinger12 software suite.

Figure 7. Example use of the JChemPaint
applet embedded into the gVTS. This
particular example illustrates the userdrawn structure of Staurosporine.
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Figure 8. Illustration of VTS screen results page. The results of the screening of Staurosporine
against a set of kinases.

Application of VTS to Identify Protein Targets of Natural Products in Drug Discovery
Natural Products and VTS
Natural products have historically been of interest to the drug discovery community.
However, despite the availability of a wide range of drug discovery techniques and the growing
number of synthetic compound libraries the number of newly discovered drugs has dropped in
recent years. This trend has largely been the impetus for the renewed interest in natural products
in drug discovery13–19. Moreover recent advances in extraction, purification and structure
determination techniques along with improved screening methods such as miniaturized high-
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throughput phenotypic assays have made it less challenging for natural products to be
interrogated with respect to their potential as therapeutic.20–22
The initiative to screen a collection of natural products described in this work consisted
of two separate subtasks. Both tasks essentially amounted to a combination of conventional
virtual screening and virtual target screening in a sense that the collections of natural product
compounds were screened against a collection of proteins in the VTS database. One task
involved screening of a publically available set of natural products from the Developmental
Therapeutics Program (DTP) of the National Cancer Institute (NCI). Another task was screening
of non-public set of natural products from the Center for Drug Discovery (CDD) and Innovation
at the University of South Florida (USF) in Tampa. The NCI set contains publicly accessible
compounds and it includes molecules which have been mentioned in various published studies
and have experimental data available to public. This means that in principle the results of VTS
screen can be compared and possibly correlated with the available experimental data reported
elsewhere. In contrast to the NCI set, CDDI set consists largely of molecules with little or no
publicly available data. This means that it may be impossible to correlate the results of the VTS
screen with any experimental data. However even without experimental consensus VTS can be
used to gauge the potential of a natural product as to its likelihood of binding to target proteins.

Materials and Methods
Virtual Compound Libraries
The NCI Diversity Set I, consisting of 1,990 virtual compounds, was obtained from the
National Cancer Institute’s (NCI) Developmental Therapeutics Program (DTP) and used as
described previously for our VTS system5,23.
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The NCI natural Product Set II includes 120 compounds2. Due to cost and time
considerations, we selected 67 compounds that ranged from 314 to 692 Daltons in a loose
application of “Lipinski’s rule of 5”. These compounds were screened in VTS. The NCI DTP
website also provides links to published experimental data on the compounds in their virtual
libraries24. This allows for comparison and validation of VTS “hits” against known
experimentally-determined interactions of the compounds when the data is available.
The CDDI library provided to us contained virtual structures for 160 natural product
compounds, many originating from marine sources25. These are from the larger collections at the
CDDI, which include over 2,500 extracts and 950 characterized bioactive compounds. Again,
due to cost and time consideration, we selected 87 of these compounds for VTS testing with a
range of 350–675 Daltons.

Ligand Preparation
Prior to screening all compounds were prepared using the LigPrep utility in Schrodinger's
Maestro software.26,27 LigPrep generates 3D structures of all tautomers, ionic states and
stereoisomers of input compounds. In the case of NCI compounds the structure files have
indicated chiralities of some stereo centers. Therefore, when preparing the ligands, only the
unspecified centers were allowed to sample different chiralities. For CDDI compounds however,
to reduce computational time and the amount of isomers, all the chiralities were inferred from the
3D structure. As a result, LigPrep generated a total of 1133 structures from the 67 original NCI
compounds and, because no chiralities were varied in the case of CDDI set, a total of only 103
structures resulted from LigPrep for the 87 original CDDI compounds.
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Virtual Target Screening
We selected primarily human proteins as the targets for this VTS exercise, which yielded
1,059 target grids representing 1,011 unique crystal structures. For this exercise with a large
number of MOIs to process in VTS, we estimated there would be over one million docking and
scoring calculations. Therefore, the compounds were divided into 25 separate files, each
containing subsets of 30–60 structures. This was done to effectively parallelize the VTS
calculations. Each of these subsets was then uploaded through the VTS web interface’s MOI
upload section. A screening job was then launched from the VTS web interface for each of the
25 subsets to be screened against all 1,059 target grids. On average each job took approximately
30 hours to complete. When analyzing the results of the screening jobs, a compound-protein was
deemed to be a “hit” if the score outperformed the average score for the top 20 NCI diversity set
compounds for that protein structure. The “hits” were compared against the literature for
consistency with published experimental data. The PubChem database was used to look-up
experimental activities for the compounds that hit one or more targets.28,29

Hardware
VTS was originally developed and run on a Dell Precision 490 workstation running
Fedora 8 Linux with dual Xeon 3.06 GHz processors, 4 GB RAM and a 250 GB hard drive. This
was sufficient when running one or a few MOIs but, for the larger sets of MOIs for the 67 NCI
natural products and the 87 CDDI natural products, we incorporated execution on a local cluster
we have developed in the Virtual Screening & Molecular Modeling Core at H. Lee Moffitt
Cancer Center & Research Institute. This cluster is comprised of 6 racks each containing 8 Intel41

based dual core desktop computers connected via a NETGEAR Pro Sage 16 router (model
GS716T).

Graphics and Modeling
Visualization of docked MOIs in protein targets was performed with Schrödinger’s
Maestro, a graphical user interface that allows modeling and facilitates use of many of
Schrödinger’s applications with the models, such as MacroModel and Glide5,11,30. Refined
depictions used for publication figures were developed using Schrödinger’s PyMol.31

Results
VTS on NCI Natural Products
Upon compilation of the results of all the jobs, a total of 13,278 hits were identified for
the NCI Natural Products Set II compounds tested. For 4 of the screened NCI molecules VTS
identified a total of 16 targets against which screened compounds were found active in one or
more experimental assays (Table 2). The most “active” MOI Daunorubicin (Figure 9) hit a total
of 6 unique proteins. The most interesting of those hits can be considered the Lck tyrosine kinase
protein. Daunorubicin has hit 5 different structures that represent this protein. Moreover in at
least two reported assays Daunorubicin had indeed shown activity against this particular target. It
may be speculated that a compound hitting multiple structures of the same protein may indicate
likely activity against that protein. In addition, results of the NCI natural products screen show
preference of some compounds towards one or more protein families as can be seen in the case
42

of Wortmannin and a kinase family (Table 2). It should be noted however that kinases are
disproportionally well represented (25%) in our protein database due to their importance in
cancer. Still an insight like this can be used to gauge the potential for more specific targeting as
well as possible promiscuity of an MOI.

Table 2. Top NCI natural products screen hits. Compounds with known activity against the
targets that have been identified as hits in the VTS screen. Column 1 contains the NSC
number of the compound, column 2 contains the common name of the compound, column
3 contains 2D sketch of the compound, column 4 contains the name of the protein targeted
by the compound, column 5 shows the number of unique structures representing the target
identified as a hit for the given MOI, column 6 is the number of assays that have reported
activity of the MOI against this target.
NSC Compound
Name

82151 Daunorubicin

Structure

Target

# of unique
structures
identified by
VTS*

# of assays
reporting
activity

Lck tyrosine kinase 5(11)

2

Estrogen Receptor
2(6)
Alpha

8

Epidermal Growth
3(5)
Factor Receptor

1

Thyroid hormone
receptor

4

1(6)

Mitogen Activated
1(39)
Protein Kinase 14

1

Fyn tyrosine kinase 1(3)

1
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Table 2 (Continued)
5159

Chartreusin

221019 Wortmannin

345647 Chaetochromin

Urokinase-type plasminogen
activator**

2(35) 1

Heat Shock Protein HSP 90-alpha***

1(13) 1

Cyclin-Dependent Kinase 5

1(2)

Cyclin-Dependent Kinase 2

6(105) 1

Serine/threonine kinase PIM1

2(17) 1

Src tyrosine kinase

2(36) 1

Lck tyrosine kinase

1(11)

2

Cyclin-Dependent Kinase 5

1(2)

1

3-phosphoinositide-dependent protein
kinase 1

1(9)

1

Glutathione-S-transferase Omega 1

1(3)

2

1

* - Number in brackets denotes the total number of structures in VTS database.
** - VTS screening included and hit the human version of the protein while the experimental
data is on mouse.
*** - VTS screening included and hit the human version of the protein while the experimental
data is on a structurally similar Plasmodium falciparum.
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Figure 9. Daunorubicin docked into Lck. Daunorubicin’s docked pose according to the VTS
docking procedure. Inset shows the local hydrogen bond interactions in yellow dashed lines as
well as the residues with which these interactions are formed in stick representation. The Lck
structure was 1QPJ.pdb.32
VTS on CDDI Natural Products
The screening of CDDI compounds against our database has also yielded interesting
results. Although assay information is not as readily available for these compounds, the results of
the VTS can still show interesting trends and insights valuable for drug discovery. Table 3 shows
the top 40 hits where the MOI has outperformed the top performers of the calibration set by the
largest margin, thus making these compounds more likely to be tighter binders to the indicated
targets. It can be seen that there are a number of molecules, as identified by their unique
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molecular weight that hit several targets, as is especially the case with compounds 374, 587 and
629. Once again, this may be an early indicator of potentially promiscuous compounds. At the
other end of the spectrum are compounds such as 287, 368 (Figure 10), 437, 530 and 674. These
compounds only hit one target. Especially interesting are those compounds with lower molecular
weight as it is easier for a larger compound to score high based on the increased number of
favorable interactions it can form with the protein. If a smaller sized yet still a drug-like
compound such as 368 significantly outperforms a calibration set for a single particular target, it
may be worthy of a further inquiry as a potential binder to that protein.
Table 3. Top CDDI set hits. Top 40 hits based on the largest margin by which an MOI
outperformed the top 20 calibration set average. First column contains the name of the
target protein with co-crystallized ligand identifier in square brackets. Second column
indicates the percentage by which a given MOI outscored the average docking score of the
top 20 calibration set molecules for that target. Third column contains the rounded
molecular weight of a docked MOI and serves as its identifier. The table is sorted by the
molecular weight.
Outperformed
calibration by (%)

Molecular Weight
(compound ID)

[R11]Coagulation factor x

28

287

[L1G]HCK

28

368

[NHB]Histone deacetylase 8

30

372

[NHB]Histone deacetylase 8

24

372

[NHB]Histone deacetylase 8

36

374

[AO5]Methionine aminopeptidase 2

35

374

[GIP]Protein (lactoylglutathione lyase)

35

374

[NHB]Histone deacetylase 8

29

374

[GIP]Protein (lactoylglutathione lyase)

30

374

[AO2]Methionine aminopeptidase 2

23

374

Target
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Table 3 (Continued)
[NHB]Histone deacetylase 8

26

437

[NHB]Histone deacetylase 8

23

530

[HYF]Orphan nuclear receptor pxr

35

587

[HYF]Orphan nuclear receptor pxr

33

587

[QPP]CAMK1D

32

587

[SWF]CYP2C9

26

587

[DEO]Macrophage metalloelastase

20

587

[XLD]Coagulation factor x heavy chain

30

587

[RAP]Fkbp25

36

587

[SDK]Cathepsin K

30

587

[POS]Cathepsin K

30

587

[INA]Cathepsin K

29

587

[POS]Cathepsin K

28

587

[BOG]p38-alpha(MAPK14)

25

587

[2CA]Cathepsin k

27

587

[FMM]Epidermal growth factor receptor

23

625

[L1G]HCK

39

629

42

629

31

629

[CIU]Epoxide hydrolase 2- cytoplasmic

29

629

[POS]Cathepsin K

33

629

[471]Peroxisome
receptor
[U66]Protein
subunit

proliferator

activated

farnesyltransferase

alpha
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Table 3 (Continued)
[SDK]Cathepsin K

31

629

[HYF]Orphan nuclear receptor pxr

25

629

[155]Urokinase-type plasminogen activator

27

629

[SAH]Histamine MeXferase (Ile105Var)

22

629

[AIJ]Estrogen receptor

21

629

21

629

[BOG]p38-alpha(MAPK14)

23

629

[LA1]Integrin alpha-L

31

663

[LA1]Integrin alpha-L

19

674

[BNE]Protein
subunit

farnesyltransferase

alpha

Discussion
We have used 67 compounds from the NCI Natural Products Set II to test our VTS
system for its ability to virtually identify potential protein targets, i.e. “hits” that can be
compared to published data for those compounds. We have also used 87 compounds from
the CDDI natural products to assess their potential interactions with protein targets when
they were screened through VTS. The work has also brought to light improvements that
can be made to the current VTS system to make it more applicable to our new areas of
application in drug discovery and development: infectious diseases and natural products,
particularly marine natural products. There is an unmet need for large-scale drug discovery
efforts with marine natural products.34,35 There is also opportunity for these large-scale
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Figure 10. 368 docked into HCK. 368’s docked pose according to the VTS docking
procedure. Inset shows the local hydrogen bond interactions in yellow dashed lines as well
as the residues with which these interactions are formed in stick representation. The HCK
structure was 2COI.pdb.33

efforts with marine natural products and natural products in general to be used more in academic
settings, such as the CDDI.36 Drug discovery efforts with marine natural products have been
successful with 13 products in clinical trials in 2010 and so these efforts should be expanded to
take advantage of new natural products from new marine sources.37 In order to scale-up these
efforts and make them more productive, particularly as natural product libraries grow, innovation
is needed.38 We believe that VTS is an innovative, cost-effective approach to address the needs
for rapid identification and appraisal of natural products. Besides our previous paper23 in which
we compared our VTS results against experimental data focusing on kinases, there are other
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recent reports in which other groups have compared results from computational drug repurposing
applications against experimental data demonstrating the usefulness of the tools.39,40
This exercise demonstrates that VTS can identify potential promiscuity of natural product
compounds that may deter further development of an MOI if the promiscuity is experimentally
confirmed for some of the “hit” proteins. VTS can also give ideas of other targets that may not
have been considered previously for the MOI. However, since our VTS protein collection is
limited, we cannot yet consider the VTS runs as comprehensive searches. There may be more
proteins that would arise as “hits” for these compounds if those proteins had been included.
Other systems are now available online for screening compounds against collections of protein
structures, such as HitPick,41 ChemMapper,42 and Mantra.43 A comparison of VTS and other
target finding applications was beyond the scope of this study since our purpose was to analyze
VTS with regards to natural products and infectious disease targets. However, we did test two of
the top scoring compounds (wortmannin and daunorubicin) from the NCI Natural Products II
and got similar hits of kinase proteins as were found by HitPick. A thorough study comparing the
various target finding applications is certainly warranted now that more applications are
published but it should be comprehensive with regards to ligands (small synthetic molecules and
natural products). We believe the VTS approach has benefits in that it can be used towards
different sites on a protein, such as allosteric sites, for which there may not be any previously
known ligands. We can use Schrödinger’s SiteMap as a means of identifying potential binding
sites [54,55].44,45 The drug-like molecules of the NCI Diversity set can quickly calibrate new
sites even when there is no previous data. Many other applications are dependent on previously
known ligands for specific binding sites in order to make their assessment of an MOI’s
interactions.
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VTS also can be used to compare an MOI against known inhibitors of VTS “hit” proteins
and to compare the MOI against its own analogs to test focusing by functional groups as rational
design is applied to the MOI to generate improved analogs. Some of the analogs may show more
specificity to the intended target and generate fewer VTS “hits”, suggesting that the analog is an
improvement over the original MOI. With regards to a known inhibitor, if the MOI shows more
specificity (fewer VTS “hits”) than the inhibitor, this can increase interest for the MOI.
The main purpose of VTS is to identify new targets for an MOI, whether they are new
targets for repurposing or targets that may indicate possible adverse interactions. For VTS to be
effective towards this purpose, we need to increase our collection of proteins. Since VTS was
originally developed for supporting oncological drug discovery projects, the emphasis was for
inclusion of primarily human proteins. For testing compounds in VTS for infectious disease
projects, we need a great increase in protein structures from viruses, bacteria and other
microorganism that are relevant to those diseases. We need to grow the VTS protein collection as
much as possible using as many structures from the Protein Data Bank, but we still want to focus
on those structures that have high resolution (~2.0 Å or less) and primarily wild-type proteins.
We realize now that, even towards oncological drug discovery, proteins from microorganisms
are important in VTS since often the beneficial microbes in the patient’s gut microbiota can be
adversely affected by drug therapy. And of course there need to be more proteins represented for
the problematic microorganisms in infectious diseases.
We intend also to include more proteins involved in protein-protein interactions. The
target sites may be more difficult to isolate for Glide grids and so multiple copies of the protein
structure with grids at different sites could be used. We can use Schrödinger’s SiteMap utility to
identify potential binding sites as part of the protein preparation and center the Glide grids on
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those sites.44 Disruptors of protein-protein interactions can conceivably be larger than typical
small molecule substrates of enzyme active sites and so we would want to expand VTS to deal
with larger MOIs. This would require an additional approach to calibrating the prepared proteins.
We can envision using a designed virtual di-, tri- or tetra-peptide or peptidomimetic library for
an additional set of averages to use in calibration and VTS analysis. These averages of larger
molecules would be of use for larger MOIs, which can occur with natural products. Another
possible improvement is to incorporate into VTS an assessment of ligand binding efficiencies.
We can improve overall interpretation of VTS dockings by taking into account the number of
non-hydrogen atoms to avoid inflation of the scores for larger ligands. The basic approach would
be to divide the GScore by the number of non-hydrogen atoms. In addition, approaches being
developed to assess drug-likeness need to be incorporated, such as the QED approach.46 Another
issue to address in improving VTS is the quality of the prepared proteins. MacroModel has been
used in VS and VTS for achieving a relaxed state, more in vivo-like, for the protein compared to
the original crystal structure. However, we might think of this as local relaxation of protein
domains, whereas a thorough molecular dynamics (MD) relaxation of the protein, in which it is
put in a virtual environment that simulates the individual water molecules and ions, can relax the
protein to a global energy minimum in solution that may be even more pertinent to creating the
protein in a realistic state for screening. In the last few years MD applications, such as
Schrödinger’s Desmond, have become available so that we can now implement MD into our
protein preparation steps.47 This implies that we should reprocess our existing protein collection
with MD as well as apply MD to new proteins. MD requires more powerfully processing power
and memory, which we can now access with clusters making these improvements feasible.
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VTS and VS are developed primarily towards screening for non-covalent interactions of
ligands and proteins. High-throughput virtual screening of potential covalent inhibitors has not
been developed to our knowledge. This would be an interesting addition but does present many
difficulties, even to develop a limited application. It would require a list of potential reactant
groups, identifying key reactive residues in a protein that could be in play, and an algorithm to
compare distances, charges and intermediates. It would seem to preclude the actions of cofactors
and other agents. So covalent screening, at least with current tools, would be too challenging.
However, it is interesting to contemplate such tools and their potential benefits in drug discovery.

Conclusion
This work has shown the potential for VTS with natural products to identify targets that
may represent new purposes for the MOI, possible promiscuity of an MOI, or possible adverse
interactions that warrant further investigation. Our VTS system can serve these purposes but we
have used this current work to identify issues to improve in order to maximize the use and
benefits of VTS for infectious disease drug discovery projects, particularly with newly acquired
marine natural products.

Using molecular modeling, chemo- and bioinformatics to search for biomolecular targets of
vitamin E δ-tocotrienol
Introduction
Vitamins, a subclass of natural products, have long been thought to play an important role
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in physiology of living organisms. Many essential processes in the human body rely on the
availability of vitamins. At the same time, while few dispute the importance of vitamins, in many
cases their precise mode of action that manifests into health benefits remains elusive. This is not
surprising however, as understanding the underpinnings of a biological effect of a small
molecule requires the knowledge of its biomolecular target. Zeroing in on the precise mode of
action of many vitamins is made more complicated by the fact that many come in various forms
and induce a range of physiological responses. Vitamin E (VE) is good example of such
complexity. VE is an essential lipid-soluble vitamin and an important macronutrient that has long
been thought to have strong antioxidant effects without causing major toxicity in humans.48–50
Its primary activity has been attributed to its ability to reduce free radicals to prevent lipid
peroxidation of polyunsaturated fatty acids.51 VE consist of 8 naturally occurring isomers, dalpha-, d-beta-, d-gamma-, and d-delta-tocopherols and d-alpha-, d-beta-, d-gamma-, and d-deltatocotrienols.52 Among the constituents of VE, tocopherols have initially received a great deal of
attention from scientific community due to their potent antioxidant properties and their
abundance in common food sources. Recently however the focus has been shifting towards
tocotrienols which, although rare in nature, have exhibited a number of physiological effects that
include neuroprotective, antioxidant, anticancer, cholesterol lowering and other therapeutic
activities.53–57 The diversity and, at the same time, specificity of physiological responses to
tocotrienols may mean that their modes of action differ from the broad antioxidant activity of
tocopherols. A quick look at the structures of tocopherols and tocotrienols reveal three double
bonds in the farnesyl isoprenoid tail of the tocotrienols making it a less flexible of the two
classes of compounds (Figure 11). This additional restraint on the conformational freedom of
tocotrienols however may be the reason for the more specific range of activities. The
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significantly reduced number of allowable conformations of tocotrienols over tocopherols may
result in the increased affinity of tocotrienols towards a specific group of binding partners. If this
is true, tocotrienols' activity goes beyond that of a broad antioxidant and into the signaling realm.
Studies of Vitamin E delta-tocotrienol (VEDT) have already proposed the notion that at least
VEDT's anti-cancer activity may be attributed not to its antioxidant properties but rather to its
involvement in the signaling pathways of cancer.58–60 Furthermore VEDT was proposed to act as
a mediating substance in antiproliferative and apoptotic mechanisms in carcinogenic tumor
cells.52,56,58,61–64 Present study attempts to gain insight into possible modes of action of the
Vitamin E δ-tocotrienol (VEDT) by using molecular modeling, chemo- and bioinformatics to
propose VEDT's likely binding partners.
To complement experimental efforts directed at pinpointing molecular target(s) of VEDT
this study takes advantage of in silico approaches to interrogate the protein space for potential
targets. As the in silico target discovery gained prominence as viable tool in the at various stages
of research campaigns, a number of methodologies have been developed to take advantage of
computational efficiency and storage capabilities of computer systems to search for potential
protein targets.65–71
In this study a number of different approaches were used to computationally probe for
potential target proteins of VEDT. Moreover, the methods used in this study vary significantly in
their approach yet aim to solve the same problem. This was done in part to decrease the effect of
errors resulting from each individual tool. More importantly the results drawn from the
consensus reached via the utilization of different approaches have shown to produce more
reliable results.72–75 One method called Virtual Target Screening (VTS) is based on the explicit
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δ-tocopherol

δ-tocotrienol

Figure 11. Comparison of the structures of δ-tocopherol and δ-tocotrienol. The additional double
bonds of δ-tocotrienol make it more conformationally constrained which can lead to its increase
preference towards particular type of targets.

modeling the intermolecular interactions between VEDT and its potential targets via a docking
protocol designed specifically to search for targets of small drug- or natural product-like
compounds.10,76 Other methods PharmMapper77,78 and PASS (Prediction of Activity Spectra of
Substances)79–81 take a chemoinformatics approach to proposing potential target of a molecule of
interest. Here the structure of VEDT and its pharmacophore is compared to a database of
structures and pharmacophores of small molecules with known biomolecular targets. The target
proteins are then proposed based on the structural similarities between database compounds and
VEDT. Lastly binding site analysis tool ProBiS82–85 was used to mine the Protein Data Bank86,87
for proteins containing binding pockets similar to those that are likely to accommodate VEDT.
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Methods
VEDT Preparation.
3D coordinates of VEDT and δ-tocopherol were downloaded from PubChem (citation) in
an SDF (Structure Data File) format and were prepared using a LigPrep27 module of the suite of
molecular modeling software Schrodinger26 with default settings corresponding to physiological
pH.

Virtual Target Screening.
VTS, a web-based software deployed on a private computer network of the Moffitt
Cancer Center10,76 was used as a molecular modeling component of this study. VTS was used to
identify potential binding partners of VEDT by the means of molecular docking. The MOIs
(VEDT and δ-tocopherol) were docked into each of the protein in the library. In addition to
human protein structures which comprise the majority of the VTS library (~1000) structures
from other organisms ranging from bacteria to mammals were also present and were included in
VEDT screen for completeness. Once docked, MOIs’ docking performance as measured by their
docking scores were compared to those of the calibration set compounds for each protein. A
protein was considered a hit if MOI’s docking score was better than the average docking score of
the top 200 calibration compounds docked into the protein.

PharmMapper.
PharmMapper uses pharmacophore mapping to identify potential targets for the MOI. Six
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pharmacophore features including hydrophobic center, positively charged center, negatively
charged center, hydrogen bond acceptor and donor vectors and aromatic plane of an ensemble of
the MOI conformations are mapped onto a library of pharmacophores extracted from publicly
available crystal structures of protein-ligand complexes. A fit score between the MOI's
pharmacophores and those in the library is then calculated and N best fitting targets are
suggested. The SDF file of VEDT structure downloaded from PubChem was converted to Tripos
mol2 file using OpenBabel software (citation). The resulting mol2 file was submitted to
PharmMapper server at http://59.78.96.61/pharmmapper.

PASS (Prediction of Activity Spectra of Substances).
PASS predicts biological activity of the MOI based on the Multilevel Neighborhoods of
Atoms (MNA)88 structural descriptors of compounds and a training set of structure-activity
relationship (SAR) data for over 60,000 chemical substances (SAR Base). For each biological
activity, based on the similarity of MNA descriptors of the MOI and the substances in the SAR
Base PASS outputs two probabilities, the probability of the MOI to exhibit the activity and the
probability of the MOI to not exhibit the activity. To execute PASS prediction SMILES chemical
identifier representing VEDT CC1=C2C(=CC(=C1)O)CCC(O2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C was extracted from
PubChem entry for VEDT and submitted to http://www.pharmaexpert.ru/passonline/predict.php.
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ProBiS (Protein Binding Sites Detection).
ProBiS identifies in the PDB (Protein Data Bank) proteins structurally similar to the
user-supplied protein of interest (POI). The algorithm behind ProBiS server represents the entire
proteins as graphs where vertices correspond to functional groups of surface amino acids and
edges represent distance between these functional groups. Pairwise alignment of structural
features of the POI and the proteins in PDB is then performed and results are displayed sorted by
the statistical Z-scores, with the proteins most similar to POI displayed on top. PDB code for
Estrogen Receptor β (ERβ) 1NDE89 and was used as the input for the ProBiS search. The choice
of the above PDB code was based on the results of the VTS screen.

Results
The VTS screen of both VEDT and δ-tocopherol have resulted in a number of proteins
that were hits for VEDT but not for δ-tocopherol (Table 4).
Table 4. VEDT and δ-tocopherol VTS results. Hit - proteins into which an MOI docked with a
score that outperformed the top 200 molecules of the calibration set. Hit* - identifies top hits;
proteins into which an MOI docked with a score that outperformed the top 20 molecules of the
calibration set.
δtocopherol
Result

[Native ligand] Protein

PDB Code

VEDT
Result

[Mon]Estrogen receptor beta

1NDE

Hit*

Not a Hit

[ZEB]Cytidine Deaminase

1CTU

Hit*

Hit

[MOF]Progesterone receptor

1SR7

Hit*

Hit

[Proflavin]Alpha-Thrombin

1BCU

Hit

Not a Hit
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Table 4 (Continued)
[CL3]Cell division protein zipA

1Y2G

Hit

Not a Hit

[D91]Coagulation factor x- heavy chain

1WU1

Hit

Not a Hit

[SRL]Orphan nuclear receptor pxr

1ILH

Hit

Not a Hit

[_U]Cytidine Deaminase

1AF2

Hit

Hit

[TTB]Retinoic acid receptor beta

1XAP

Hit

Not a Hit

[442]Thyroid hormone receptor beta-1

1R6G

Hit

Not a Hit

[L79]Retinoic acid receptor rxr-alpha

1RDT

Hit

Not a Hit

[STR]Igg1-kappa db3 fab (light chain)

1DBB

Hit

Not a Hit

[E1P]Peptidyl-prolyl cis-trans isomerase a

1W8M

Hit

Not a Hit

[AO5]Methionine aminopeptidase 2

1R58

Hit

Not a Hit

[SDK]Cathepsin K

1AU0

Hit

Not a Hit

[FSN]Thrombin light chain

1OYT

Hit

Not a Hit

[R11]Coagulation factor x

1G2M

Hit

Not a Hit

[HEM]albumin (no iron)

1N5U

Hit

Not a Hit

[ANO]Igg1-kappa db3 fab (light chain)

1DBK

Hit

Not a Hit

[L10]Mitogen-activated protein kinase 14

1W82

Hit

Not a Hit

[AB8]Integrin alpha-I

1XDG

Hit

Not a Hit

[FPP]Protein farnesyltransferase

1FPP

Hit

Not a Hit

[IGN]Prothrombin

1K21

Hit

Not a Hit

[DHZ]Cytidine Deaminase

1CTT

Hit

Not a Hit

[MSC]HIV-1 Protease

1D4J

Hit

Not a Hit

[L08]Integrin alpha-I

1RD4

Hit

Not a Hit

{CI1031(Z34)]Coagulation Factor XA

1FJS

Hit

Not a Hit

[BLN]Cathepsin s

1MS6

Hit

Not a Hit

[AIH]Estrogen receptor

1XP1

Hit

Not a Hit

[CMB]Blood coagulation factor xa

1LPZ

Hit

Not a Hit

[RTR]Coagulation factor xa- heavy chain

1NFY

Hit

Not a Hit

[EST]Estradiol receptor

1QKT

Hit

Not a Hit

[STU]Tyrosine-Protein Kinase zap-70

1U59

Hit

Not a Hit

[Palmitate]Lipocalin Beta-Lactoglobulin

1B0O

Hit

Hit

[AIU]Estrogen receptor

1XP6

Hit

Not a Hit
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Table 4 (Continued)
[AAY]Integrin alpha-I

1XDD

Hit

Not a Hit

[HYC]Type117 beta-hydroxysteroid
dehydrogenase

1I5R

Hit

Not a Hit

[CIU]Epoxide Hydrolase

1EK1

Hit

Not a Hit

[165]Prothrombin

1SB1

Hit

Hit

[CIU]Epoxide hydrolase 2- cytoplasmic

1VJ5

Hit

Hit

[HYF]Orphan nuclear receptor pxr

1M13

Hit

Hit

[337]map kinase 14

3CTQ

Hit

Hit

According to VTS, ERβ (PDB code 1NDE) was a top hit for VEDT and while not being
a hit for δ-tocopherol (Figure 12). 33 other proteins were also predicted as potential hits for
VEDT but not for δ-tocopherol. This is consistent with some experimental findings that support
binding of VEDT to ERβ.55,60 Moreover some patterns or at least consistencies may be observed
by looking at the VTS hit list. In particular, a number of hormone and nuclear receptors can be
seen in the proposed list of targets. This is not surprise however, as ProBis search for binding
sites similar to the ERβ reveals that the binding sites of a number of proteins such as Rxr-like
protein, retinoic acid receptor rxr-α, progesterone receptor and others are indeed quite similar
(Table 5).
PharmMapper prediction resulted in 300 proposed pharmacophores with those fitting the
flexible alignment with VEDT ranked on top. These results were examined for consistency with
the best VEDT hits from VTS screen. Ranked 51 was ERβ based on the pharmacophore derived
from the PDB structure 1NDE, same structure that represented the best hit during VTS screen.
PASS prediction resulted in proposed 500 activities which VEDT statistically is more
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Figure 12. Docked pose of VEDT as identified by the VTS. VEDT, colored in magenta forms
hydrogen bonds (yellow dashed lines) with GLU 305 and ARG 346.
Table 5. Results of the ProBis query based on the PDB ID 1NDE input structure. The list reveals
structures in the Protein Data Bank that contain binding site similar to that of ERβ as represented
by the structure under the PDB ID 1NDE.
PDB ID Protein Name
2j7y

ESTROGEN RECEPTOR BETA

3uud

ESTROGEN RECEPTOR

3ltx

ESTROGEN RECEPTOR

2e2r

ESTROGEN-RELATED RECEPTOR GAMMA

3mnp

GLUCOCORTICOID RECEPTOR

2q1h

ANCCR
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Table 5 (Continued)
1xiu

RXR-LIKE PROTEIN

4fne

STEROID RECEPTOR 2

3k6p

STEROID HORMONE RECEPTOR ERR1

1g2n

ULTRASPIRACLE PROTEIN

4e2j

ANCESTRAL GLUCOCORTICOID RECEPTOR 2

3vhv

MINERALOCORTICOID RECEPTOR

1t7r

ANDROGEN RECEPTOR

2p1t

RETINOIC ACID RECEPTOR RXR-ALPHA

3ry9

ANCESTRAL GLUCOCORTICOID RECEPTOR 1

1z5x

ULTRASPIRACLE PROTEIN (USP) A HOMOLOGUE OF RXR

3dzu

RETINOIC ACID RECEPTOR RXR-ALPHA

1sr7

PROGESTERONE RECEPTOR

3plz

FTZ-F1 RELATED PROTEIN

1hg4

ULTRASPIRACLE

1lbd

RETINOID X RECEPTOR

3eyb

NUCLEAR HORMONE RECEPTOR RXR

4iqr

HEPATOCYTE NUCLEAR FACTOR 4-ALPHA

2gl8

RETINOIC ACID RECEPTOR RXR-GAMMA

2q60

RETINOID X RECEPTOR

4j5x

RETINOIC ACID RECEPTOR RXR-ALPHA, NUCLEAR RECEPTOR

1lv2
3dzu

HEPATOCYTE
FACTOR 4-GAMMA
COACTIVATORNUCLEAR
1
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA

3kmr

RETINOIC ACID RECEPTOR ALPHA

likely to exhibit than not. The results were ranked by the probability that VEDT exhibits a given
activity. Similarly these results were examined for consistency with the VTS screen and
PharmMapper prediction.
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According to the PASS prediction there are several activities related either to estrogen
modulation or the ERβ specifically (Table 6).

Table 6. PASS prediction results. Predicted activities with relation to the estrogen modulation or
action of ERβ. Rank – overall PASS rank of this activity by VEDT. Pa – Probability that VEDT
exhibits the given activity. Pi – Probability that VEDT does not exhibit the given activity.
Rank

Pa

Pi

Activity

213

0,177

0,022

Estrogen antagonist

234

0,148

0,024

Estrogen receptor beta

247

0,140

0,026

Estrogen
antagonistagonist

371

0,048

0,021

Estrogen beta receptor
agonist

According to PASS, among the estrogen related activities VEDT is likely to serve as
estrogen antagonist with highest probability, followed by ERβ antagonist, followed by estrogen
agonist, followed by ERβ agonist. Based on this result, VEDT is more likely to serve as an
antagonist of estrogen and ERβ activity rather than their agonist.

Discussion
Consensus between Computational Studies
Identification the potential molecular targets of VEDT has been attempted via a
combination of molecular modeling (docking), chemoinformatics (SAR) techniques and
bioinformatics in the form of binding site analysis, The results show consistency in identifying
ERβ as a potential target of VEDT. All three approaches VTS, PharmMapper and PASS have
identified ERβ modulation as one of the potential activities of VEDT. In particular VTS has
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identified ERβ as represented by PDB ID 1NDE as a top target from a list of 1451 protein
structures. Although PharmMapper and PASS algorithms operate on a substantially larger data
space, still they were able to identify ERβ as a potential target, although didn’t rank it as high as
VTS. Moreover PharmMapper exhibited consistency in preference towards the conformation of
the ERβ represented by 1NDE, hinting at possible antagonistic mechanism of action.60,89 The
hypothesis of the antagonistic mode of action can also be favored based on the results of PASS
which favored an antagonistic activity of VEDT towards ERβ than that of an agonistic.

Consistency with Experimental Data
Although no experimental data was considered during the initial VTS screening of
VEDT, subsequent literature search revealed that Comitato and colleagues had performed both
the in vitro binding analyses and molecular docking studies to identify a high affinity interaction
between VEDT and ERβ, a first evidence for such an association reported59,60. The consistency
of experimental data with the computational approaches reported in this work is encouraging and
gives validity to the use of tools such as VTS to probe for potential molecular targets of
compounds with an unknown mode of action. In addition the use of the techniques described in
this work allows for additional inferences regarding the precise modulating effect of the MOI on
its target. Although Comitato and co-workers, based on the docking studies, favored an agonistic
mode of action and seem to contradict the preference towards an antagonistic activity favored by
our results, the combination of different approaches reported here can be beneficial in facilitating
the investigation of the true mode of action of the MOI.
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Overall, the use of VTS, particularly in combination with other methods aimed at
achieving similar goals via different approaches, is a viable strategy in helping identify potential
targets of natural products and other chemical substances. Moreover utilization of bioinformatics
approaches like ProBis can help gain additional insight into potential targets and help identify
structures for further inclusion into the VTS and chemoinformatics screens. This multi-pronged
consensus approach may prove especially valuable in cases where it is not feasible or otherwise
prohibitive to conduct experimental studies to address this question.
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CHAPTER FOUR:

CHARMMING DRUG DESIGN DATABASE AND ADDITIONAL MODULES
DEVELOPMENT
CHARMMing Drug Design Database
Database design considerations
Successful design of any data driven application relies heavily on its data storage and
management backbone. Poor database design choices made at the inception of the project can
significantly hinder the development at any point. Moreover, particularly damaging setbacks
may result if poor design choices become apparent at later stages of the project life cycle. It
seems difficult however to foresee all the use cases of the application, all the functionality and
changes in specifications along the way. The dynamic nature of the application is especially
characteristic of open source projects where the development contributions often take the project
in the directions not initially intended or designed for.
To design a database that can efficiently and intuitively store data for a wide range of
applications pertaining to a particular field one does not need to foresee all the use cases of the
application. The database should not aim to achieve a particular usage profile. What database
should do is to model the particular phenomenon or its targeted “universe” or a field which it is
to represent. In the case of CHARMMing drug design database this “universe” is a field of drug
design and discovery. Although in the case of CHARMMing, the field is narrowed specifically to
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computer-aided drug discovery, the underlying data structures should ideally reflect the fact that
this field is a part of larger field.
How does modeling the “universe” as a whole help design a better database for an
application with particular usage scenarios? Any scenario that can be incorporated in an
application and any use case will undoubtedly involve some aspects of the field that the
underlying database is designed to model. It can also be said that a particular use case is not
likely to involve all possible aspects of the field. At the same time however, a use case will never
involve any aspects of fields completely outside of the one modeled by a database. As an
example of the former case, a rigid protein docking is not going to care about existence of
multiple protein conformations. This doesn’t mean that there shouldn’t be a data structure that is
designed to hold such information because flexible-protein docking, which is certainly within the
realm of computer-aided drug discovery, will use this knowledge, thus the need for the
representative data structures is necessitated. On the other end of the spectrum, the database
designer can safely assume that there is no need to incorporate data structures storing the
information regarding accounts receivables since accounting is rather different “universe” from
computer-aided drug discovery and does not need to be represented in the database.
CHARRMing’s initial functionality already included modeling of proteins and the data
structures that represent the target portion of the computer-aided drug discovery “universe” were
already in place. To make the model of the entire “universe” more complete, the efforts to
develop CHARMMing docking module included supplementing the existing database with data
structures representing small molecule world and its relationship and interactions with the target
world. Some additional data structures pertaining to targets were also added to more completely
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represent the aspects of computer-aided drug discovery. The data structures to explicitly store
information regarding the following entities were included:


Target data
o Proteins, protein conformations, binding sites, residues, amino acids



Ligand/Substrate data
o Ligands, fragments, de novo ligands, poses



Analysis
o Molecular interactions, scoring, object attributes, metrics



Infrastructure
o File and job management

Additionally, although explicit data structures weren’t created, a link to the outside databases
was established to fetch experimental results for the purpose of creating predictive models for
(Quantitative) Structure-Activity Relationship ((Q)SAR) studies.

Dynamic Relationship Schema
When designing a database for a project that is projected to have frequent addition of new
modules and functionality over its lifetime it becomes a challenge to keep the complexity of the
database in check while at the same time accommodating for the “unknown” future functionality.
Specifically, number of tables storing new types of objects defined by new modules will grow
linearly with the number of new objects. To keep flexibility in assigning attributes to object (i.e.
to be able to assign any number of attributes to any number of object) many-to-many
relationships will need to be defined between all the object types and their corresponding
attributes. To accomplish this conventional database design approach dictates the need for a triad
76

of tables for each type of object to store the data pertaining to the object along with an indefinite
number of attributes (Figure 13).

Figure 13. The triad of tables dictated by traditional database design approach to define an
object. In this case DockedPose, its attributes and a many-to-many relationship between them,
described in the “Docked Pose Attribute Lookup” table.

The total number of tables required to store object-attribute data using this conventional
approach is 3*N where N is a number of different types of objects. To curb the growth of the
number of tables while, at the same time, allow for flexibility necessary for a project with a yet
undefined future functionality an unconventional design approach was taken. In this approach
here termed dynamic relationship all of the object types still reside in their respective tables.
However all the attributes, independent of the possible object affiliations are defined in one table.
In addition, and this is the key concept of the approach, all of the object-attribute associations are
stored in a single table. To specify which object a particular attribute relates a separate field is
used where the name of the table of the particular object type is stored (Figure 14).
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Figure 14. The layout of the dynamic relationship schema. The objects (enclosed in the black
frame) each reside in their respective tables as in the conventional design approach. The
attributes all reside in a single table irrespective of their applicability to a particular type of
object. ObjectAttributes table specifies the relationship between a specific attribute and a specific
object by means of the ObjectID as dynamic foreign key to a table specified in the
ObjectTableName field.

The dynamic relationship schema design reduces the number of tables from 3*N to N+2,
a three-fold reduction in the number of tables. This design allows linking any object with any
attribute even if the link may seem less than intuitive during design time but becomes apparent
during development of a particular module. Additionally, because many objects in
CHARMMing have association with data residing outside of the database on a local file system
as flat text files same dynamic approach was used to link objects with paths to files on disk. The
dynamic relationship approach facilitates any type of future development within and outside of
the scope of molecular modeling or computer-aided drug discovery as the design is non-specific
yet highly flexible.
. One potential disadvantage of dynamic relationship approach is that the queries to
retrieve the data become more complicated. However, in cases where the database access is
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handled by the ORM (object-relational mapping) as is the case with the Django engine which
makes up the backbone of the CHARMMing web server, this is not an issue since the type of
objects (i.e. the table name criteria) can be easily specified as an additional tern in the filter
clause of the ORM API (application program interface) when interrogating the database.

CHARMMing Fragment-Based de novo Drug Design Module
Introduction
Another in silico approach that is part of the computer-aided drug design methodology is
de novo ligand design. In this approach, unlike docking or virtual screening where a set of
ligands are docked into the protein binding site, the ligands are constructed de novo. In other
words, novel ligands are constructed as a result of this approach. There are a number of various
approaches to this method. Atom-based design assembles or grows ligands atom by atom.1
Fragment-based approach starts with a set of low molecular weight fragments and assembles
novel ligands using them as building blocks. 2–6 There are advantages and disadvantages to these
two approaches. Atom-based approach can sample a larger chemical space and result in a
proposal of more diverse set of novel ligands. The disadvantage is however that the proposed
ligands are more likely to be difficult to synthesize or even represent highly unrealistic
structures.3 Fragment-based approaches, to a degree, address the problem of unrealistic structures
by using fragments commonly found in known molecules and result in more drug-like structures.
This however keeps fragment-based approaches largely within the confines of relatively well
explored chemical space and sacrifices diversity and novelty for the synthetic feasibility. Still
however, it remains a significant challenge to ensure that compounds proposed by de novo
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approaches are readily synthesizable and much effort has gone into incorporating synthetic
feasibility analysis into such approaches.3–6
Fragment-based approaches, in turn utilize variety of methods to both generate the de
novo structures and evaluate them in regards to their potential as a substrate for a particular
target. Two major components of the approach to the structure generation are ligand-based and
structure-based. In ligand-based design, construction of the de novo ligand is guided by reference
to other known ligand(s), pharmacophores or scaffolds.7–12 In the case of structure-based
approach, the de novo design is guided primarily by the character of the binding site and
evaluated solely based on the fragments’ and ligand’s interactions with the target.13–16 Logically,
there exist a number of methods where the above two approaches are combined in one way or
another. 2,17–19 There are certain trade-offs between choosing a particular approach to fragmentbased de novo design. Ligand-based methods somewhat alleviate the problem of synthetic
accessibility of proposed ligands if novel ligands are forced by the evaluation conditions to be
highly similar to known easily synthesizable structures. On the other hand, such an approach
results the diversity and novelty of the proposed structures in comparison to a purely target
structure-based approach.
Despite the lingering issue of synthetic feasibility of ligands generated by the fragmentbased approaches fragment-based de novo design methods have advantages over conventional
virtual screening. Molecular fragments, although highly promiscuous when docked individually
result in high ligand efficiency (LE). That is high predicted affinity (docking score) per heavy
atom. If a novel compound is constructed from highly efficient fragments, the overall efficiency
stays at a high level in a fully assembled ligand without the promiscuity of its individual building
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blocks. The LE of novel ligands that result from such an approach is likely to be higher than that
of an average ligand in a virtual screening library.

Fragment-Based de novo Design Protocol Implementation in CHARMMing
Similarly to the docking protocol described in the chapter two, CHARMMing’s
fragment-based de novo ligand design protocol is based on programs developed in the group of
Prof. Caflisch at University of Zurich. 2,20,21 To serve as starting material, a library of 3,252
fragments is pre-loaded into CHARMMing and is accessible to all users. This library is based on
the Maybridge Hitfinder™ set (www.maybridge.com) on which public ligand library pre-loaded
into CHARMMing is based as well. To generate the fragment set program DAIM
(Decomposition And Identification of Molecules)21 was used with default settings. The
fragments were then atom-typed and parametrized for compatibility with CHARMM
Generalized Force Field (CGenFF).22–25
De novo design protocol, outlined in Figure 15 consists of the following steps:
1. Each fragment selected by user is docked into the user-specified binding site using
the program SEED (Solvation Energy for Exhaustive Docking).20 More detailed
mechanism of this fragment docking step is described in chapter two as this step is
identical to the corresponding step of the CHARMMing’s fragment docking
protocol.
2. Program GANDI2 with a CGenFF compatible parameter file created and
customized for this project is then used to join the docked fragments. The
fragments are connected to each other in an iterative fashion using a set of preloaded linker fragments and a procedure that grows the “connected” ligand by
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randomly linking “disconnected” fragments and evaluating the fitness of the
resulting structure using the island model genetic algorithm. All de novo ligands
consisting of 2 and 3 fragments are evaluated in this manner. The fitness metric is
a GANDI scoring function that incorporates protein-ligand van der Waals and
electrostatic interactions as well, intra ligand interactions between fragments and
linkers and penalties for unfavorable dihedral angles between newly connected
fragments.2
3. Top 20 ligands that have passed the energy cutoff are then atom-typed and
parametrized to CGenFF standards using the program MATCH (Multipurpose
atom-typer for CHARMM)26 for further processing by CHARMM program.
Number of ligands to be kept for further processing is a user-modifiable parameter.
4. Each ligand pre-processed in previous step is then incorporated into a ligand-target
CHARMM compatible system and minimized using the adopted basis NewtonRaphson (ABNR) for thousand steps while keeping the protein atoms fixed. The
resulting CHARMM interaction energy values are recorded and the final pose of
the ligand within the binding site of the target is also scored with SEED in its
“evaluation only” mode.
5. The consensus ranking approach used in the docking protocol and described in
chapter two is utilized to assign final rankings to the newly constructed ligands.
The consensus ranking is based on three scores GANDI score, CHARMM total
interaction energy, and SEED total energy.
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Figure 15. Flow chart of the CHARMMing’s fragment-based de novo design procedure.
Procedure starts with a pre-loaded library of fragments which are first docked using SEED
program. Then GANDI joins docked fragments to form new ligands. Top ligands are then atomtyped and then parametrized using MATCH. Final series of steps involve minimization with
CHARMM, evaluation with SEED and consensus ranking using GANDI score, CHARMM and
SEED energies.

The specification of binding site is also identical to the docking protocol and allows user
to use a co-crystallized ligand, if present, to define a binding site, or define a custom binding site
using a graphical point-and-click interface that is part of the CHARMMing’s drug design
module.
The fragment-based de novo approach currently implemented in CHARMMing is purely
target structure-based and the evaluation of each new ligand’s fitness is only dependent on the
energetics of its interaction with the target and itself. GANDI however is a program that
combines both structure-based and ligand-based construction and evaluation of the generated
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ligands. The ligand-based criteria can be incorporated in a number of ways. A user can specify a
template ligand which can serve as either a 2D or 3D reference during the de novo design
procedure. In this case the similarity metric between each newly constructed ligand and the
template is added to the GANDI scoring function with a user-defined weight coefficient. This
allows the user to put high emphasis on the similarity aspect of the procedure. Similarly a
pharmacophore definition can be supplied in place of the template ligand, analogously affecting
the GANDI scoring function. The incorporation of the template and pharmacophore specification
into the CHARMMing’s fragment-based de novo design interface is currently under
development.
The interface of the CHARMMing’s fragment-based de novo design protocol is almost
identical to that of the docking protocol (Figures 16 and 17) and incorporates a list of pre-loaded
fragments on the job submission page as well as reflects the nature of the ligand construction
protocol in the newly designed ligand names and scores.

CHARMMing QSAR/SAR Module
Introduction
A major component of computer-aided drug discovery is using known information to
make informed decisions regarding the direction of a research campaign. Specifically, this
involved building predictive models that infer a compound’s potential activity based on its
features (mainly structural) and data available from other experiments. The models constructed
in the context of this approach fall into two categories, structure-activity relationship (SAR)28
and quantitative structure-activity relationship (QSAR)29. This type of predictive modeling has
initially found most application during the lead optimization stage of the discovery campaign
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Figure 16. CHARMMing’s fragment-based de novo design job submission page. This page
differs from docking submission page in the list of starting molecules. Here pre-loaded fragment
set consisting of 3252 fragments is presented as a starting material.

where a number of both pharmacodynamics and pharmacokinetic properties can be optimized
by iteratively applying (Q)SAR models to lead compounds and their derivatives.30–32 Specifically
potency, selectivity and specificity towards a particular target as well as absorption, distribution,
secretion, metabolism and excretion collectively called ADME are among properties often
sought to be improved using predictive modeling. Among the advantages of using (Q)SAR at
early stages of the discovery campaign is the methodology’s ability to help identify undesirable
compounds that are potentially highly promiscuous, toxic, or otherwise show lack of potential to
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Figure 17. CHARMMing’s fragment-based de novo design job details/results page. This page
differs from docking job details/results page in the naming of the newly constructed ligands and
the scores involved in the consensus ranking. Here the de novo ligands reflect the naming of the
genetic algorithm and GANDI score replaces docking’s FFLD27 score.

be developed into a drug. This saves money by helping avoid high expenditures by discarding
potentially problematic compounds at earlier stages of the drug discovery pipeline before
committing substantial resources to the development and evaluation of drug candidates.33–35
Predictive modeling have found wide use in industrial design, regulatory assessment of
pharmaceutical agents, pesticides and other substances.36,37 Additionally, (Q)SAR models have
found increasing use as an alternative to animal testing in cases where there is a push to actively
steer away from methods that utilize animals for compound testing.38,39 Recently (Q)SAR
modeling has been finding applications in conjunction with other computational drug discovery
approaches such as virtual screening in addition to applications in substance risk assessment.40
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However, the predictive performance and quality of (Q)SAR models in many respects lags
behind other areas of machine learning applications and warrant improvements.41
As part of the efforts to address some of the shortcoming of (Q)SAR several SAR models
have been developed based on such machine learning qualifiers as random forest42,43 and k
Nearest Neighbor Simulated Annealing.44 These efforts helped lead to the identification of novel
non-nucleoside chemical motifs as well as Candesartan, a drug used in treatment of hypertension
and heart failure, for NS5B, hepatitis C virus RNA polymerase activity.45 This section describes
implementation of the above and other models in the context of the development of the new
(Q)SAR module of the CHARMMing web server.46

(Q)SAR Functionality of CHARMMing
(Q)SAR workflow in CHARMMing consists of two main components - model training
and prediction. It is necessary to create a predictive model or use existing model before
predictive analysis can be performed.
To train a model user can upload an SDF (structure data file) file that contains
compounds’ structural information as well as other descriptors and metrics. To perform SAR
prediction the training set needs to contain binary (Yes/No, Active/Inactive, etc.) activity metric.
For QSAR models numerical activity values (e.g., IC50) need to be present in the training set.
CHARMMing also provides interface to access PubChem Bioassay database that accepts a
search criteria from the user and relays it to PubChem servers via PUG REST (Power User
Gateway Representational State Transfer) and SOAP (Simple Object Access Protocol)
interfaces.47–52 The search returns a list of assays with link to the detailed information on
PubChem website and an option to download an SDF representing the structures with
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corresponding structure/assay metrics. This file can then be directly submitted for model training
into CHARMMing (Figure 18). List of models available through CHARMMing interface for
training is listed in Table 7. Once the SDF is submitted, the user is asked to choose the property
from the SDF (binary for SAR, numerical for QSAR) to use as a metric for model building. Once
this selection is made the model building commences. Model training job is processed using
CHARMMing’s job infrastructure utilized by all the other modules.
Once training is complete the model is saved in the database and is only accessible to the
user that has created it. User can view all the models created in the past along with the pertinent
model information that among other things helps assess the quality of the model and its ability to
produce reliable predictions. The screenshot of the model information screen in Figure 19 is an

Figure 18. CHARMMing (Q)SAR model training file upload interface. Categorization models
are used for SAR, Regression for QSAR. Currently available models with brief description are
listed in Table 7.

example of a Random Forest Categorization model and includes among other metrics the
following measures of model quality – cross validation53, y-randomization54, area under the
curve (AUC)55, precision and. Pearson correlation coefficient R2 is presented for regression
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Table 7. List of predictive models available through CHARMMing.

Figure 19. CHARMMing (Q)SAR model details screen. The screen presents user with the basic
information about the job as well as common metrics to assess the predictive power and
reliability of the model. Additionally, here user can run predictions based on this job.

models. The model details screen is where a user can initiate prediction based on the model by
uploading an SDF file with the test set structures.
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The progress of any training or prediction job can be monitored in real time in a similar
manner as other modules implemented in charming. Additionally SAR and QSAR tutorials are
provided to introduce the user to the concept of predictive modeling as well as provide a guided
walkthrough using the dataset used in the NS5B study.45
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Computational Chemistry Education with CHARMMing
Introduction
One of the primary purposes of CHARMMing is to serve as a bridge between the
powerful capabilities of molecular modeling tools and a user that may not have capacity or
technical expertise to operate these tools in their “raw” form. Aside from targeting academic labs
and scientists that use CHARMMing to facilitate their research, the web interface provides a
perfect means to serve another important need – chemistry education, and not necessarily just
computational chemistry education. Basic chemistry concepts can be reinforced or approached
from a different, possibly more engaging angle via the use of molecular dynamics.56,57 Most,
especially non-commercial, molecular modeling software is not easy to use and requires
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knowlede of program specific scripting syntax in additiona to some technical expertise. It has
been argued however, that the problem of software complexity can be overcome by “friendly
web interfaces” or via the use of bootable media with pre-installed software.58 CHARMMing, of
course takes the former approach. Without the need to learn scripting languages or even look at
somewhat intimidating program scripts, with a familiar point-and-click style of visual interface
and engaging graphics CHARMMing has a potential to capture students that would be turned off
by the complexity of molecular modeling. There are several factors that make CHARMMing
espeicially attractive as an engaging educational tool:


Ability to perform many common molecular modeling and drug design tasks



Ability to monitor progress of jobs in real time



Ability to perform tasks in different order



Ability to visualize and graphically manipulate systems



Availability of tutorials for most tasks incorporated into CHARMMing

To further increase usefullness of CHARMMing as an educational tool an interactive
lessons module have been added to the web server and described in a series of papers.59–61 Here
an overview of the lessons module is given along with exapmles of lessons incorporated into
CHARMMing and their application as educational tools.

Design and Implementation of CHARMMing Lessons Module
In order to increase CHARMMing’s lessons module’s value as an educational tool,
several design considerations and functionalities were taken into account:


Provide a range of interactive lessons from the basic introductory to more

advanced.
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Provide the students with the ability to track their progress in real-time. The

student should be able to know where and at which step they are in a particular lesson, at
as well as how does a particular lesson fit into a greater view of molecular modeling.


The module should identify mistakes made by the student during the course of the

lesson, provide meaningful feedback and allow correction of such mistakes in order to
proceed with the lesson plan.


Provide the user with ability to perform different taks to accomplish similar goals

along with explanation of the differences and the applicability domain of each approach.


Provide the means for educators to create new lessons and workflows for

students.
CHARMMing incorporates primarily a structure centric workflow. That is, before any
tasks can be performed a protein structure needs to be provided. This can be done via a query to
PDB or a user specification. At the point of structure submission, a user is given the option to
make the structure part of a particular lesson. Once the structure is associated with a lesson, any
task that is performed with the structure is compared to the lesson plan for that particular lesson
and the feedback to the user is provided. If, for example, user performs minimization on a
structure where, according to lesson plan solvation was warranted first, the lesson progress
indicates that solvation was not performed and the lesson cannot proceed until it is. Similarly if
the task that is performed by the user is the correct task but with incorrect parameters (e.g.
number of minimization steps is different from that in the lesson plan) the progress report notes
that the minimization needs to be re-run because the parameter value was not correct. The
overview of the overall lesson progress is updated in real time and is part of the navigation pane
present on every page of the web site. The lesson progress also includes links to the details of
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each step (Figure 20). Currently a total of seven lessons have been incorporated into
CHARMMing:
1. Lesson one: Introduction. Introduction to the basic features of CHARMMing as
well as basic principles of structure preparation and molecular dynamics
simulation.
2. Lesson two: Simulation proteins. A lesson designed for a more thorough
investigation of molecular dynamics of proteins.
3. Lesson three: Enhanced sampling/Self-guided Langevin dyamics (SGLD).
Intorduces students to a different flavor of protein dynamics to study
conformational changes.
4. Lesson four: Custom residue topology files (RTF), quantum mechanics/molecular
mechanics (QM/MM). An introduction to the hybrid QM/MM simulations and a
closer look at the files representing structure topology in CHARMM .
5. Lesson five: Coarse grained modeling. Introduction to the representation of
protein at a lower resolution by using “beads” representing groups of atoms and
using this approach to investigate larger scale conformational changes in
proteins.60
6. Lesson six: Oxidation/Reduction Calculations. Allows students to investigate the
process of electron donation and utilize the graphical interface to perform amino
acid mutations.61
7. Lesson seven: Molecular docking. An introduction to the concept of docking as a
tool of the computer-aided drug design on an example of a self-dock.
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In addition to the above lessons CHARMMing provides functionality to create new
lessons by “recording” steps performed by a user into a lesson plan. If, for example, user checks
“Start Lesson Recording” when initially uploading the structure, performs solvation,
minimization and runs dynamics, all of these steps with the corersponding parameters for each
task will be saved as a lesson plan and presented as a custom lesson.
In addition to the lessons module, a series of CHARMM/CHARMMing tutorials are
available at http://www.charmmmtutorial.com. The tutorials cover all the concepts on that serve

Figure 20. Examples of lesson progress bar. Three snapshots of a lesson progress of an
“Introduction to Simulation” lesson. Student’s progress in the entire lesson is shown. Clicking on
“Failed” link takes student to the details of that particular step with explanation of failure and
steps necessary to resume the lesson.

as a scientific base for CHARMMing and include walkthroughs of common workflows such as
molecular dynamics simulations, docking studies, predictive modeling and others. Together with
CHARMMing lessons these resources play a role beyond education. Most importantly they help
ensure proper usage of CHARMMing and the tools it provides, highlight the importance of
critically evaluating the results and promote proper scientific practices.
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Conclusion
The wide range of functionality already available through CHARMMing and currently
under development would not be possible without contribution from experts from a variety of
fields within and outside of molecular modeling and computer-aided drug discovery. Moreover
important design considerations at each step of development made it possible to unify and bring
under one umbrella the diversity of the fields of molecular modeling and computer-aided drug
discovery. The results of these efforts serve an important need and bring the power and variety of
computational tools to those that have least access to them yet could gain the most from their
use. With this however, the contributors to CHARMMing as well as to other open source
scientific tools carry a burden of responsibility. Although one of the primary goals is that the
fruits of their labor help make science more accessible, it is even more important that opensource scientific resources ensure that the science facilitated by these tools is sound. While
making complex concepts more palatable to the user, it is imperative to make user realize the
limitations of the approaches involved and the fact that results should often be taken with a grain
of salt. CHARMMing contributors attempt to accomplish this mission by implementing only
published and well-reviewed, well tested methods, by providing tutorials and lessons, by
incorporating penalties into custom ligands whose structures are too “different” from existing
force field parameters, by including confidence and performance metrics for (Q)SAR predictive
models, by providing means to visually inspect the structures and monitor jobs output. The steps
to ensure proper use of tools often require substantial effort. However it is the responsibility of
the contributors to ensure that the methods implemented as part of these projects have solid
scientific foundation. Moreover it is important that the interfaces and the workflows, however
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friendly they may be, encourage critical evaluation of the results and promote the soundness of
the scientific research.
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APPENDIX A
Permission to Print CHARMMing Fragment-Based Docking Paper

Figure A1. Permission to print Fragment-Based Docking: Development of the CHARMMing
Web User Interface as a Platform for Computer-Aided Drug Design
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Permission to Print VTS Paper

Figure A2. Permission to print Virtual Target Screening: Validation Using Protein Kinases
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Permission to Print CHARMMing (Q)SAR Paper

Figure A3. Permission to print Development and Implementation of (Q)SAR modeling within
the CHARMMing web-user interface
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